CN103249733A - 用于治疗或预防轻度认知障碍的稠合的三唑 - Google Patents

用于治疗或预防轻度认知障碍的稠合的三唑 Download PDF

Info

Publication number
CN103249733A
CN103249733A CN2011800518621A CN201180051862A CN103249733A CN 103249733 A CN103249733 A CN 103249733A CN 2011800518621 A CN2011800518621 A CN 2011800518621A CN 201180051862 A CN201180051862 A CN 201180051862A CN 103249733 A CN103249733 A CN 103249733A
Authority
CN
China
Prior art keywords
compound
optionally substituted
ring
salt
reaction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2011800518621A
Other languages
English (en)
Chinese (zh)
Inventor
小池竜树
中村实
远又庆英
高井隆文
帆足保孝
梶田雄一
塚本彻哉
鎌田信
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda California Inc
Original Assignee
Takeda California Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45094181&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN103249733(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda California Inc filed Critical Takeda California Inc
Publication of CN103249733A publication Critical patent/CN103249733A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CN2011800518621A 2010-09-02 2011-09-01 用于治疗或预防轻度认知障碍的稠合的三唑 Pending CN103249733A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2010-197064 2010-09-02
JP2010197064 2010-09-02
JP2011-143548 2011-06-28
JP2011143548 2011-06-28
PCT/JP2011/070419 WO2012029991A1 (en) 2010-09-02 2011-09-01 Fused triazoles for the treatment or prophylaxis of mild cognitive impairment

Publications (1)

Publication Number Publication Date
CN103249733A true CN103249733A (zh) 2013-08-14

Family

ID=45094181

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2011800518621A Pending CN103249733A (zh) 2010-09-02 2011-09-01 用于治疗或预防轻度认知障碍的稠合的三唑

Country Status (22)

Country Link
US (3) US8901309B2 (enExample)
EP (1) EP2611805A1 (enExample)
JP (1) JP5871909B2 (enExample)
KR (1) KR20130139895A (enExample)
CN (1) CN103249733A (enExample)
AR (1) AR082865A1 (enExample)
AU (1) AU2011296887A1 (enExample)
BR (1) BR112013004746A2 (enExample)
CA (1) CA2809779A1 (enExample)
CL (1) CL2013000575A1 (enExample)
DO (1) DOP2013000051A (enExample)
EA (1) EA201390333A1 (enExample)
EC (1) ECSP13012535A (enExample)
MA (1) MA34556B1 (enExample)
MX (1) MX2013002511A (enExample)
PE (1) PE20131305A1 (enExample)
PH (1) PH12013500403A1 (enExample)
SG (1) SG187917A1 (enExample)
TW (1) TW201213327A (enExample)
UY (1) UY33586A (enExample)
WO (1) WO2012029991A1 (enExample)
ZA (1) ZA201301929B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2011007756A1 (ja) * 2009-07-13 2012-12-27 武田薬品工業株式会社 複素環化合物及びその用途
MX2013002511A (es) * 2010-09-02 2013-07-29 Takeda Pharmaceutical Triazoles fusionados para el tratamiento o profilaxis de daño cognitivo moderado.
EP2687528A1 (en) * 2012-07-17 2014-01-22 Ares Trading S.A. Fused triazole derivatives as gamma secretase modulators
RU2563254C2 (ru) * 2013-07-08 2015-09-20 Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Московский государственный университет имени М.В. Ломоносова" (МГУ) Способ получения производных 7-(гетеро)арил-4,5,6,7-тетрагидро[1,2,3]триазоло[1,5-a]пиридина
JP7000160B2 (ja) * 2015-05-12 2022-01-19 エフ エム シー コーポレーション 除草剤としてのアリール置換二環式化合物
US11603440B2 (en) * 2019-09-12 2023-03-14 Dupont Electronics, Inc. Polyimide films and electronic devices
EP4448100A4 (en) * 2021-12-17 2025-10-22 Athira Pharma Inc USES OF BICYCLIC COMPOUNDS FOR THE TREATMENT OF DISEASES

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1992618A1 (en) * 2006-03-09 2008-11-19 Eisai R&D Management Co., Ltd. Polycyclic cinnamide derivative
WO2010083141A1 (en) * 2009-01-16 2010-07-22 Bristol-Myers Squibb Company Bicyclic compounds for the reduction of beta-amyloid production

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1261610A2 (en) 2000-02-17 2002-12-04 Bristol-Myers Squibb Pharma Company Succinoylamino carbocycles and heterocycles as inhibitors of a-beta protein production
MXPA05012281A (es) 2003-05-14 2006-05-19 Torreypines Therapeutics Inc Compuestos y uso de los mismos en la modulacion beta amiloide.
EP1678172B1 (en) * 2003-10-15 2009-12-09 Targacept, Inc. Azabicyclic compounds for relieving pain and treating central nervous system disorders
BRPI0511504A (pt) 2004-05-26 2008-01-22 Eisai R&D Man Co Ltd composto ou um sal farmaceuticamente aceitável do mesmo, e, agente preventivo ou terapêutico para uma doença resultante de beta-amilóides
EP1808432B1 (en) 2004-10-26 2010-02-24 Eisai R&D Management Co., Ltd. Amorphous form of cinnamide compound
AU2007205066A1 (en) 2006-01-11 2007-07-19 Merck & Co., Inc. Fused triazole tachykinin receptor antagonists
TWI378091B (en) 2006-03-09 2012-12-01 Eisai R&D Man Co Ltd Multi-cyclic cinnamide derivatives
TW200808800A (en) 2006-05-05 2008-02-16 Astrazeneca Ab MGluR5 modulators V
EP2119719A1 (en) 2006-12-26 2009-11-18 Daiichi Sankyo Company, Limited Thiazepine derivative
WO2008077649A1 (en) 2006-12-26 2008-07-03 Gilead Sciences, Inc. Pyrido(3,2-d)pyrimidines useful for treating viral infectons
AU2008214372A1 (en) 2007-02-08 2008-08-14 Merck Sharp & Dohme Corp. Therapeutic agents
MX2010006243A (es) 2007-12-06 2010-08-31 Schering Corp Moduladores de gamma secretasa.
JP2010197064A (ja) 2009-02-23 2010-09-09 Chugoku Electric Power Co Inc:The 直下位置測定装置
JP2012051807A (ja) 2009-02-26 2012-03-15 Eisai R & D Management Co Ltd アリールイミダゾール化合物
EP2615090A1 (en) * 2009-02-26 2013-07-17 Eisai R&D Management Co., Ltd. Nitrogen-containing fused heterocyclic compounds and their use as beta amyloid production inhibitors
JP2012051806A (ja) * 2009-02-26 2012-03-15 Eisai R & D Management Co Ltd イミダゾリルピラジン誘導体
WO2011002067A1 (ja) 2009-07-02 2011-01-06 武田薬品工業株式会社 複素環化合物およびその用途
JPWO2011007756A1 (ja) 2009-07-13 2012-12-27 武田薬品工業株式会社 複素環化合物及びその用途
US8946266B2 (en) 2009-07-15 2015-02-03 Janssen Pharmaceuticals, Inc. Substituted triazole and imidazole derivatives as gamma secretase modulators
TWI468402B (zh) 2009-07-31 2015-01-11 必治妥美雅史谷比公司 降低β－類澱粉生成之化合物
US8637525B2 (en) 2009-07-31 2014-01-28 Bristol-Myers Squibb Company Compounds for the reduction of beta-amyloid production
WO2011016559A1 (ja) 2009-08-07 2011-02-10 武田薬品工業株式会社 複素環化合物およびその用途
JP2011143548A (ja) 2010-01-12 2011-07-28 Panasonic Corp スクリーン印刷機及びスクリーン印刷方法
EP2523949B1 (en) 2010-01-15 2014-08-20 Janssen Pharmaceuticals Inc. Novel substituted triazole derivatives as gamma secretase modulators
MX2013002511A (es) * 2010-09-02 2013-07-29 Takeda Pharmaceutical Triazoles fusionados para el tratamiento o profilaxis de daño cognitivo moderado.

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1992618A1 (en) * 2006-03-09 2008-11-19 Eisai R&D Management Co., Ltd. Polycyclic cinnamide derivative
WO2010083141A1 (en) * 2009-01-16 2010-07-22 Bristol-Myers Squibb Company Bicyclic compounds for the reduction of beta-amyloid production

Also Published As

Publication number Publication date
WO2012029991A1 (en) 2012-03-08
TW201213327A (en) 2012-04-01
EP2611805A1 (en) 2013-07-10
PH12013500403A1 (en) 2013-03-25
US8822699B2 (en) 2014-09-02
DOP2013000051A (es) 2013-04-30
KR20130139895A (ko) 2013-12-23
US20120059030A1 (en) 2012-03-08
UY33586A (es) 2012-03-30
AR082865A1 (es) 2013-01-16
US8901309B2 (en) 2014-12-02
MA34556B1 (fr) 2013-09-02
EA201390333A1 (ru) 2013-08-30
JP2013536798A (ja) 2013-09-26
AU2011296887A1 (en) 2013-04-11
ZA201301929B (en) 2013-11-27
SG187917A1 (en) 2013-04-30
CA2809779A1 (en) 2012-03-08
US20140350260A1 (en) 2014-11-27
MX2013002511A (es) 2013-07-29
BR112013004746A2 (pt) 2016-06-07
ECSP13012535A (es) 2013-06-28
JP5871909B2 (ja) 2016-03-01
PE20131305A1 (es) 2013-10-31
US20130178497A1 (en) 2013-07-11
CL2013000575A1 (es) 2013-08-23

Similar Documents

Publication Publication Date Title
CN103842356B (zh) 用于治疗神经变性疾病的1‑芳基羰基‑4‑氧‑哌啶化合物
CN114341127B (zh) 作为hpk1抑制剂的氨基吡嗪化合物及其用途
EP3026051A1 (en) Heterocyclic compound
CN114144230B (zh) 作为eed和prc2调节剂的大环唑并吡啶衍生物
CN121159541A (zh) 通过缀合btk抑制剂与e3连接酶配体降解布鲁顿氏酪氨酸激酶(btk)及其使用方法
WO2011002067A1 (ja) 複素環化合物およびその用途
AU2013253516A2 (en) Nitrogenated heterocyclic compound
TW201811771A (zh) 苯並咪唑類化合物激酶抑制劑及其製備方法和應用
WO2008016131A1 (en) Fused heterocyclic compound
TW201609726A (zh) 作為ｌｓｄ１抑制劑之咪唑并吡啶及咪唑并吡嗪
CN103249733A (zh) 用于治疗或预防轻度认知障碍的稠合的三唑
CN104755465A (zh) 杂环化合物
JP5722781B2 (ja) 縮合複素環誘導体およびその用途
CN103402995B (zh) 吲哚、吲唑衍生物或其盐
CN103998432A (zh) 双环化合物
EP2597095A1 (en) Fused heterocyclic compound and application thereof
CN115260180A (zh) 含三氮唑稠环类衍生物、药物组合物及其制备方法和应用
JP5888702B2 (ja) 抗癌活性化合物
WO2012008508A1 (ja) 複素環化合物
WO2013100018A1 (ja) 複素環化合物
WO2013005354A1 (ja) 複素環化合物
CN104245698B (zh) 含氮杂环化合物
JP2012136500A (ja) 複素環化合物
WO2025143152A1 (ja) チアゾリル－ピラゾロ［１，５－ａ］ピリジン化合物、およびそのＭＹＬＫ４阻害剤としての使用

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
AD01 Patent right deemed abandoned
AD01 Patent right deemed abandoned

Effective date of abandoning: 20170329